Jasper Therapeutics Initiates Strategic Review Including Asset Sale, Merger or Wind-Down
JSPR•Jasper Therapeutics’ board has launched a comprehensive review of strategic alternatives, including asset sales, licensing deals, mergers or an orderly wind-down, to maximize shareholder value. The company will also evaluate cost-saving measures and maintain regulatory compliance while continuing development of briquilimab for urticaria and asthma.
1. Board Launches Strategic Review
Jasper’s board of directors has authorized a full review of strategic alternatives aimed at maximizing shareholder value, without a defined timeline or assurance of concluding a transaction.
2. Exploring Multiple Strategic Paths
The review encompasses a range of options, including sale or licensing of assets, collaborations, full company sale, business combinations, mergers or an orderly wind-down of operations.
3. Ongoing Cost Control and Development
To preserve cash, the company will evaluate cost-saving measures and maintain regulatory and financial reporting compliance while advancing briquilimab clinical trials in chronic spontaneous urticaria, chronic inducible urticaria and asthma.
